CureVac’s Public Market Journey Concludes Following BioNTech Acquisition

CureVac NL0015436031

The independent public listing of German biotech firm CureVac has officially ended. The company's shares have been delisted from the Nasdaq exchange, marking the final step in its complete acquisition by fellow mRNA pioneer BioNTech SE. The focus now shifts to integrating CureVac's technology and pipeline into the larger entity.

The market landscape shifted fundamentally in January 2026 with the finalization of BioNTech's takeover. As the transaction closed, the publicly available float of CureVac shares effectively dissolved. The ticker symbol "CVAC" was subsequently removed from the Nasdaq at the beginning of that month, with trading suspended. The equity's final closing price was approximately $4.66.

This delisting is a direct consequence of the completed deal, which involved several key components:

• Complete Acquisition: BioNTech has assumed control of all CureVac assets. This includes proprietary technology like the "RNA Printer" platform and ongoing oncology research projects.
• Exchange Exit: The formal delisting process from the Nasdaq has been executed.
• Squeeze-Out: Any remaining minority shareholders are being compensated through a squeeze-out procedure, with their holdings exchanged or cashed out.

Consequently, CureVac no longer exists as a standalone publicly traded security, and its shares are inaccessible to private investors.

Implications for Former Shareholders

For previous holders of CureVac stock, the investment narrative has reached its conclusion. What was once a speculative growth stock has now been finalized as a settled corporate action. Analyst recommendations and price targets for CureVac have lost all relevance following the delisting.

Key details for reference:

• Final Share Price: ~$4.66 USD
• Current Status: Delisted / Inactive
• Acquiring Entity: BioNTech SE

The acquisition resolves the financial uncertainties that had surrounded CureVac in recent years, such as clinical trial delays and funding challenges. However, the core intellectual property and technological platforms remain intact, now fully absorbed into BioNTech's strategic operations. Investors' exposure to these assets will henceforth be solely through BioNTech's corporate performance.

BioNTech Consolidates mRNA Leadership

With the transaction complete, attention turns to BioNTech's expanded footprint. The deal, valued at roughly €1.25 billion, consolidates leading German mRNA expertise within a single corporation. CureVac's research and development efforts are expected to complement BioNTech's existing programs in both oncology and vaccine development.

This integration occurs as the broader mRNA sector navigates new challenges. Ongoing legal disputes concerning potential patent infringements form part of this landscape. Notably, a lawsuit filed by Bayer in January 2026 against several mRNA-focused companies now also implicates the enlarged BioNTech group.